» Articles » PMID: 10768972

Parenteral Adjuvant Activities of Escherichia Coli Heat-labile Toxin and Its B Subunit for Immunization of Mice Against Gastric Helicobacter Pylori Infection

Overview
Journal Infect Immun
Date 2000 Apr 18
PMID 10768972
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The heat-labile toxin (LT) of Escherichia coli is a potent mucosal adjuvant that has been used to induce protective immunity against Helicobacter felis and Helicobacter pylori infection in mice. We studied whether recombinant LT or its B subunit (LTB) has adjuvant activity in mice when delivered with H. pylori urease antigen via the parenteral route. Mice were immunized subcutaneously or intradermally with urease plus LT, recombinant LTB, or a combination of LT and LTB prior to intragastric challenge with H. pylori. Control mice were immunized orally with urease plus LT, a regimen shown previously to protect against H. pylori gastric infection. Parenteral immunization using either LT or LTB as adjuvant protected mice against H. pylori challenge as effectively as oral immunization and enhanced urease-specific immunoglobulin G (IgG) responses in serum as effectively as aluminum hydroxide adjuvant. LT and LTB had adjuvant activity at subtoxic doses and induced more consistent antibody responses than those observed with oral immunization. A mixture of a low dose of LT and a high dose of LTB stimulated the highest levels of protection and specific IgG in serum. Urease-specific IgG1 and IgG2a antibody subclass responses were stimulated by all immunization regimens tested, but relative levels were dependent on the adjuvant used. Compared to parenteral immunization with urease alone, LT preferentially enhanced IgG1, while LTB or the LT-LTB mixture preferentially enhanced IgG2a. Parenteral immunization using LT or LTB as adjuvant also induced IgA to urease in the saliva of some mice. These results show that LT and LTB stimulate qualitatively different humoral immune responses to urease but are both effective parenteral adjuvants for immunization of mice against H. pylori infection.

Citing Articles

Production and Immunogenicity Assessment of LTp50: An -Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein.

Wong-Arce A, Gonzalez-Ortega O, Romero-Maldonado A, Miranda-Lopez A, Garcia-Soto M, Farfan-Castro S Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543088 PMC: 10975102. DOI: 10.3390/ph17030302.


Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.

Pitcovski J, Gruzdev N, Abzach A, Katz C, Ben-Adiva R, Brand-Shwartz M Vaccine. 2022; 40(8):1098-1107.

PMID: 35078662 PMC: 8768024. DOI: 10.1016/j.vaccine.2022.01.025.


Protection against avian coronavirus conferred by oral vaccination with live bacteria secreting LTB-fused viral proteins.

Lublin A, Katz C, Gruzdev N, Yadid I, Bloch I, Farnoushi Y Vaccine. 2022; 40(5):726-733.

PMID: 34998606 PMC: 8717763. DOI: 10.1016/j.vaccine.2021.12.053.


Evaluation of Immunogenicity and Efficacy of Tetraspanin 2 (TSP2) Fused to Heat-Labile Enterotoxin B Subunit LTB Adjuvant Following Intranasal Vaccination of Cattle.

Zerna G, Rathinasamy V, Toet H, Anderson G, Dempster R, Spithill T Vaccines (Basel). 2021; 9(11).

PMID: 34835144 PMC: 8623123. DOI: 10.3390/vaccines9111213.


Review of Newly Identified Functions Associated With the Heat-Labile Toxin of Enterotoxigenic .

Duan Q, Xia P, Nandre R, Zhang W, Zhu G Front Cell Infect Microbiol. 2019; 9:292.

PMID: 31456954 PMC: 6700299. DOI: 10.3389/fcimb.2019.00292.


References
1.
Guidry J, Cardenas L, Cheng E, Clements J . Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun. 1997; 65(12):4943-50. PMC: 175713. DOI: 10.1128/iai.65.12.4943-4950.1997. View

2.
Asaka M, Takeda H, Sugiyama T, Kato M . What role does Helicobacter pylori play in gastric cancer?. Gastroenterology. 1997; 113(6 Suppl):S56-60. DOI: 10.1016/s0016-5085(97)80013-3. View

3.
Glenn G, Rao M, Matyas G, Alving C . Skin immunization made possible by cholera toxin. Nature. 1998; 391(6670):851. DOI: 10.1038/36014. View

4.
Liang X, Lamm M, Nedrud J . Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J Immunol. 1988; 141(5):1495-501. View

5.
Czerkinsky C, Russell M, Lycke N, Lindblad M, Holmgren J . Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun. 1989; 57(4):1072-7. PMC: 313231. DOI: 10.1128/iai.57.4.1072-1077.1989. View